NV

Nuvectis Pharma IncNASDAQ NVCT Stock Report

Last reporting period 31 Dec, 2023

Updated 13 Nov, 2024

Last price

Market cap $B

0.118

Micro

Exchange

XNAS - Nasdaq

NVCT Stock Analysis

NV

Uncovered

Nuvectis Pharma Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.118

Dividend yield

Shares outstanding

14.642 B

Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. The company is headquartered in Fort Lee, New Jersey and currently employs 11 full-time employees. The company went IPO on 2022-02-04. The firm focuses on the development of precision medicines for the treatment of unmet medical needs in oncology. The company uses target selection, drug profiling, and clinical and regulatory execution to build a pipeline of anticancer targeted-therapy drugs. Its product pipeline consists of NXP800 and NXP900. The firm's lead product candidate, NXP800 is a clinical-stage, oral small-molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway. The company targets ovarian clear cell carcinoma (OCCC) and endometrioid ovarian cancer. NXP800 uses a synthetic lethality strategy to reduce the protective factors in the cell that are modified by overactivation of HSP1, with ARID1a gene defective cells being vulnerable. NXP900 is an oral small molecule designed to inhibit the roto-oncogene tyrosine-protein kinase (SRC) and YES1 kinases. The company is used for the treatment of SRC-associated solid tumors.

View Section: Eyestock Rating